File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection

TitlePriming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection
Authors
KeywordsAdeno-associated virus
Immune responses
Peptides to T cell epitopes
Receptor binding domain
SARS-CoV
Issue Date2008
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2008, v. 26 n. 13, p. 1644-1651 How to Cite?
AbstractDevelopment of vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is crucial in the prevention of SARS reemergence. The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. Our previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. In this study, we further assessed the immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone. Since T cell epitopes are highly conserved and boosting with peptides may induce the production of effector memory T cells, which may be effective against viruses with mutations in the neutralizing epitopes, our results suggest that the vaccination protocol used may be ideal for providing effective, broad and long-term protection against SARS-CoV infection. © 2008 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/68125
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorDu, Len_HK
dc.contributor.authorZhao, Gen_HK
dc.contributor.authorLin, Yen_HK
dc.contributor.authorChan, Cen_HK
dc.contributor.authorHe, Yen_HK
dc.contributor.authorJiang, Sen_HK
dc.contributor.authorWu, Cen_HK
dc.contributor.authorJin, DYen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorZhou, Yen_HK
dc.contributor.authorZheng, BJen_HK
dc.date.accessioned2010-09-06T06:01:35Z-
dc.date.available2010-09-06T06:01:35Z-
dc.date.issued2008en_HK
dc.identifier.citationVaccine, 2008, v. 26 n. 13, p. 1644-1651en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/68125-
dc.description.abstractDevelopment of vaccines against severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) is crucial in the prevention of SARS reemergence. The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. Our previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. In this study, we further assessed the immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone. Since T cell epitopes are highly conserved and boosting with peptides may induce the production of effector memory T cells, which may be effective against viruses with mutations in the neutralizing epitopes, our results suggest that the vaccination protocol used may be ideal for providing effective, broad and long-term protection against SARS-CoV infection. © 2008 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.en_HK
dc.subjectAdeno-associated virusen_HK
dc.subjectImmune responsesen_HK
dc.subjectPeptides to T cell epitopesen_HK
dc.subjectReceptor binding domainen_HK
dc.subjectSARS-CoVen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntibody Formation - immunologyen_HK
dc.subject.meshCD4-Positive T-Lymphocytes - immunologyen_HK
dc.subject.meshCD8-Positive T-Lymphocytes - immunologyen_HK
dc.subject.meshDependovirus - genetics - immunologyen_HK
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_HK
dc.subject.meshEpitopes - immunologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFlow Cytometryen_HK
dc.subject.meshImmunity, Cellular - immunologyen_HK
dc.subject.meshImmunization Scheduleen_HK
dc.subject.meshImmunization, Secondaryen_HK
dc.subject.meshImmunoglobulin G - analysis - biosynthesisen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshNeutralization Testsen_HK
dc.subject.meshReceptors, Virus - genetics - immunologyen_HK
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_HK
dc.subject.meshSARS Virus - immunologyen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - immunology - prevention & control - virologyen_HK
dc.subject.meshT-Lymphocytes - immunologyen_HK
dc.subject.meshVaccines, Synthetic - immunologyen_HK
dc.subject.meshViral Matrix Proteins - genetics - immunologyen_HK
dc.subject.meshViral Vaccines - immunologyen_HK
dc.titlePriming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=26&issue=13&spage=1644&epage=1651.&date=2008&atitle=Priming+with+rAAV+encoding+RBD+of+SARS-CoV+S+protein+and+boosting+with+RBD-specific+peptides+for+T+cell+epitopes+elevated+humoral+and+cellular+immune+responses+against+SARS-CoV+infectionen_HK
dc.identifier.emailJin, DY:dyjin@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityJin, DY=rp00452en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2008.01.025en_HK
dc.identifier.pmid18289745-
dc.identifier.scopuseid_2-s2.0-40249111494en_HK
dc.identifier.hkuros142914en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40249111494&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue13en_HK
dc.identifier.spage1644en_HK
dc.identifier.epage1651en_HK
dc.identifier.isiWOS:000254767100006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridDu, L=8686996200en_HK
dc.identifier.scopusauthoridZhao, G=8684553000en_HK
dc.identifier.scopusauthoridLin, Y=23479885500en_HK
dc.identifier.scopusauthoridChan, C=16021156900en_HK
dc.identifier.scopusauthoridHe, Y=8742157400en_HK
dc.identifier.scopusauthoridJiang, S=7404453146en_HK
dc.identifier.scopusauthoridWu, C=7501660961en_HK
dc.identifier.scopusauthoridJin, DY=7201973614en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridZhou, Y=8791655300en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats